Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters

L. R. Morgan, P. S. Schein, P. V. Woolley, D. Hoth, J. Macdonald, Marc E Lippman, L. E. Posey, R. W. Beazley

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Tamoxifen (NSC 180973; ICI 46474) can provide palliation to patients with advanced breast cancer whose tumors contain estrogen binding proteins (EBP). The drug is most effective in patients with bone metastasis and minimal prior therapy. In the present study, 72 patients with advanced breast cancer were evaluated for their response to oral tamoxifen therapy administered at a dose of 20 mg twice daily. Twenty eight of 72 patients (38%) demonstrated objective responses to tamoxifen therapy. For patients with a positive EBP and no prior chemotherapy, eight of 11 (74%) responded. No patient possessing a tumor negative for EBP achieved a remission. Patients with tumors that possessed normal arylsulfatase B and glucose 6 phosphate dehydrogenase enzyme activities responded most favorably to tamoxifen therapy. These results demonstrate that tamoxifen is effective in the treatment of patients with advanced breast cancer, and EBP and specific enzymes might be useful in selecting the patients for hormone manipulation.

Original languageEnglish
Pages (from-to)1437-1443
Number of pages7
JournalCancer Treatment Reports
Volume60
Issue number10
StatePublished - Dec 1 1976
Externally publishedYes

Fingerprint

Therapeutic Uses
Tamoxifen
Breast Neoplasms
Carrier Proteins
Estrogens
N-Acetylgalactosamine-4-Sulfatase
Therapeutics
Neoplasms
Glucosephosphate Dehydrogenase
Enzymes
Hormones
Neoplasm Metastasis
Bone and Bones
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Morgan, L. R., Schein, P. S., Woolley, P. V., Hoth, D., Macdonald, J., Lippman, M. E., ... Beazley, R. W. (1976). Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treatment Reports, 60(10), 1437-1443.

Therapeutic use of tamoxifen in advanced breast cancer : correlation with biochemical parameters. / Morgan, L. R.; Schein, P. S.; Woolley, P. V.; Hoth, D.; Macdonald, J.; Lippman, Marc E; Posey, L. E.; Beazley, R. W.

In: Cancer Treatment Reports, Vol. 60, No. 10, 01.12.1976, p. 1437-1443.

Research output: Contribution to journalArticle

Morgan, LR, Schein, PS, Woolley, PV, Hoth, D, Macdonald, J, Lippman, ME, Posey, LE & Beazley, RW 1976, 'Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters', Cancer Treatment Reports, vol. 60, no. 10, pp. 1437-1443.
Morgan LR, Schein PS, Woolley PV, Hoth D, Macdonald J, Lippman ME et al. Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treatment Reports. 1976 Dec 1;60(10):1437-1443.
Morgan, L. R. ; Schein, P. S. ; Woolley, P. V. ; Hoth, D. ; Macdonald, J. ; Lippman, Marc E ; Posey, L. E. ; Beazley, R. W. / Therapeutic use of tamoxifen in advanced breast cancer : correlation with biochemical parameters. In: Cancer Treatment Reports. 1976 ; Vol. 60, No. 10. pp. 1437-1443.
@article{2ae1515d26004229916bd900fcf3f63a,
title = "Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters",
abstract = "Tamoxifen (NSC 180973; ICI 46474) can provide palliation to patients with advanced breast cancer whose tumors contain estrogen binding proteins (EBP). The drug is most effective in patients with bone metastasis and minimal prior therapy. In the present study, 72 patients with advanced breast cancer were evaluated for their response to oral tamoxifen therapy administered at a dose of 20 mg twice daily. Twenty eight of 72 patients (38{\%}) demonstrated objective responses to tamoxifen therapy. For patients with a positive EBP and no prior chemotherapy, eight of 11 (74{\%}) responded. No patient possessing a tumor negative for EBP achieved a remission. Patients with tumors that possessed normal arylsulfatase B and glucose 6 phosphate dehydrogenase enzyme activities responded most favorably to tamoxifen therapy. These results demonstrate that tamoxifen is effective in the treatment of patients with advanced breast cancer, and EBP and specific enzymes might be useful in selecting the patients for hormone manipulation.",
author = "Morgan, {L. R.} and Schein, {P. S.} and Woolley, {P. V.} and D. Hoth and J. Macdonald and Lippman, {Marc E} and Posey, {L. E.} and Beazley, {R. W.}",
year = "1976",
month = "12",
day = "1",
language = "English",
volume = "60",
pages = "1437--1443",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Therapeutic use of tamoxifen in advanced breast cancer

T2 - correlation with biochemical parameters

AU - Morgan, L. R.

AU - Schein, P. S.

AU - Woolley, P. V.

AU - Hoth, D.

AU - Macdonald, J.

AU - Lippman, Marc E

AU - Posey, L. E.

AU - Beazley, R. W.

PY - 1976/12/1

Y1 - 1976/12/1

N2 - Tamoxifen (NSC 180973; ICI 46474) can provide palliation to patients with advanced breast cancer whose tumors contain estrogen binding proteins (EBP). The drug is most effective in patients with bone metastasis and minimal prior therapy. In the present study, 72 patients with advanced breast cancer were evaluated for their response to oral tamoxifen therapy administered at a dose of 20 mg twice daily. Twenty eight of 72 patients (38%) demonstrated objective responses to tamoxifen therapy. For patients with a positive EBP and no prior chemotherapy, eight of 11 (74%) responded. No patient possessing a tumor negative for EBP achieved a remission. Patients with tumors that possessed normal arylsulfatase B and glucose 6 phosphate dehydrogenase enzyme activities responded most favorably to tamoxifen therapy. These results demonstrate that tamoxifen is effective in the treatment of patients with advanced breast cancer, and EBP and specific enzymes might be useful in selecting the patients for hormone manipulation.

AB - Tamoxifen (NSC 180973; ICI 46474) can provide palliation to patients with advanced breast cancer whose tumors contain estrogen binding proteins (EBP). The drug is most effective in patients with bone metastasis and minimal prior therapy. In the present study, 72 patients with advanced breast cancer were evaluated for their response to oral tamoxifen therapy administered at a dose of 20 mg twice daily. Twenty eight of 72 patients (38%) demonstrated objective responses to tamoxifen therapy. For patients with a positive EBP and no prior chemotherapy, eight of 11 (74%) responded. No patient possessing a tumor negative for EBP achieved a remission. Patients with tumors that possessed normal arylsulfatase B and glucose 6 phosphate dehydrogenase enzyme activities responded most favorably to tamoxifen therapy. These results demonstrate that tamoxifen is effective in the treatment of patients with advanced breast cancer, and EBP and specific enzymes might be useful in selecting the patients for hormone manipulation.

UR - http://www.scopus.com/inward/record.url?scp=0017041430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017041430&partnerID=8YFLogxK

M3 - Article

C2 - 191185

AN - SCOPUS:0017041430

VL - 60

SP - 1437

EP - 1443

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 10

ER -